Bayesian Capital Management LP Purchases Shares of 6,578 Repligen Co. (NASDAQ:RGEN)

Bayesian Capital Management LP acquired a new position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 6,578 shares of the biotechnology company's stock, valued at approximately $947,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Signaturefd LLC lifted its holdings in Repligen by 172.2% during the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 124 shares during the last quarter. Sava Infond d.o.o. purchased a new stake in shares of Repligen during the fourth quarter valued at approximately $29,000. Itau Unibanco Holding S.A. bought a new stake in Repligen in the 4th quarter worth about $40,000. UMB Bank n.a. raised its stake in Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after buying an additional 110 shares during the last quarter. Finally, Global Retirement Partners LLC boosted its holdings in shares of Repligen by 54.0% in the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock worth $53,000 after buying an additional 129 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Repligen Trading Down 3.6 %

Shares of RGEN traded down $4.61 during trading hours on Friday, hitting $123.24. The stock had a trading volume of 580,989 shares, compared to its average volume of 727,651. Repligen Co. has a 12-month low of $102.97 and a 12-month high of $182.52. The company's fifty day simple moving average is $135.03 and its 200 day simple moving average is $145.37. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The firm has a market cap of $6.92 billion, a P/E ratio of -241.65, a P/E/G ratio of 4.54 and a beta of 1.21.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. During the same quarter last year, the firm posted $0.28 earnings per share. Repligen's revenue was up 10.4% compared to the same quarter last year. Equities research analysts forecast that Repligen Co. will post 1.72 EPS for the current fiscal year.

Insider Activity at Repligen

In other news, Director Margaret Pax purchased 250 shares of the business's stock in a transaction on Monday, March 17th. The stock was purchased at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the purchase, the director now directly owns 1,043 shares in the company, valued at $157,169.67. The trade was a 31.53 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.20% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have recently weighed in on RGEN. Evercore ISI initiated coverage on shares of Repligen in a report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price target on the stock. TD Cowen began coverage on Repligen in a research note on Monday, February 10th. They issued a "buy" rating and a $200.00 target price on the stock. HC Wainwright restated a "buy" rating and set a $180.00 price objective on shares of Repligen in a research note on Monday, May 5th. Royal Bank of Canada decreased their target price on Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a research report on Wednesday, April 30th. Finally, Canaccord Genuity Group reduced their target price on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $173.25.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.